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Abstract: The control of leishmaniases, a complex parasitic disease caused by the protozoan parasite
Leishmania, requires continuous innovation at the therapeutic and vaccination levels. Chitosan is
a biocompatible polymer administrable via different routes and possessing numerous qualities to
be used in the antileishmanial strategies. This review presents recent progress in chitosan research
for antileishmanial applications. First data on the mechanism of action of chitosan revealed an
optimal in vitro intrinsic activity at acidic pH, high-molecular-weight chitosan being the most
efficient form, with an uptake by pinocytosis and an accumulation in the parasitophorous vacuole
of Leishmania-infected macrophages. In addition, the immunomodulatory effect of chitosan is an
added value both for the treatment of leishmaniasis and the development of innovative vaccines.
The advances in chitosan chemistry allows pharmacomodulation on amine groups opening various
opportunities for new polymers of different size, and physico-chemical properties adapted to
the chosen routes of administration. Different formulations have been studied in experimental
leishmaniasis models to cure visceral and cutaneous leishmaniasis, and chitosan can act as a booster
through drug combinations with classical drugs, such as amphotericin B. The various architectural
possibilities given by chitosan chemistry and pharmaceutical technology pave the way for promising
further developments.
Keywords: chitosan; drug carriers; leishmaniasis; chemotherapy; vaccine
1. Introduction
Leishmaniases are neglected tropical and sub-tropical diseases with an estimated 0.7 to 1 million
new cases per year in nearly 100 endemic countries, caused by Leishmania spp., a protozoan parasite
transmitted by the female Phlebotomine sandfly [1,2]. About 20 Leishmania species are able to infect
humans and two main clinical manifestations are usually described: visceral leishmaniasis (VL), which is
fatal in the absence of treatment and also affects dogs, and cutaneous leishmaniasis (CL), which is
self-curing but leads to disfigurement and stigmatisation. There are other clinical manifestations
of CL including mucocutanous and diffuse forms. Whereas some vaccines exist for dogs—with
uncomplete efficacy—none are marketed for human use. Chemotherapy is presently the single
approach to manage these diseases, in combination with a more intense vector control [1]. The current
treatment recommended for leishmaniases include the pentavalent antimonials (Glucantime® and
Pentostam®), liposomal amphotericin B (AmBisome®; LampB), paromomycin used by parenteral route,
and miltefosine (Impavido®), the latter remaining the single orally active drug [3]. However, most of
these drugs have limitations of high cost, significant adverse effects, variable effectiveness and
drug resistance (for the antimonials for VL in the Indian subcontinent [ISC]); only LampB currently
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donated via WHO for VL in a single course treatment in the ISC approaches an acceptable treatment.
Therefore, there is a real need for safe, efficient, affordable, short course, oral, and field-adapted drugs
for the treatment of leishmaniases.
However, the intracellular habitat of the amastigote stage of the Leishmania parasite is a challenge
for the treatment of leishmaniases as the drug candidates have to accumulate in the phagolysosomal
compartment of the host macrophages and selectively kill the parasite without cytotoxic effects.
Different approaches have been developed to discover novel chemical entities active against the
intracellular amastigote including: (i) systematic in vitro high-through-put screening of numerous
chemical libraries, (ii) exploration of specific validated biochemical targets, (iii) immunomodulatory
and other host-related strategies, (iv) drug combinations with drugs exhibiting different mechanisms of
action, and (v) formulations to enhance the bioavailability of the classical drugs [4–8], including topical
formulations for CL that might also reduce adverse effects [9]. Chitosan, a biodegradable cationic
polysaccharide, which has direct anti-leishmanial activity, immunomodulatory activity and can be
used as a drug delivery vehicle, has proved to be attractive subject for studies on leishmaniasis.
The chemical structure of chitosan is presented in Figure 1.
Figure 1. Chemical structure of chitosan polymer.
This review aims to present the most recent findings from the literature considering chitosan and
its derivatives in different formulations for both therapeutic and vaccine purposes in the treatment and
prevention of both cutaneous and visceral leishmaniasis.
Table S1 presents the main characteristics of the chitosan-based systems that have been developed
these past years. Table S2 presents the antileishmanial and cytotoxic properties of the chitosan-based
systems also developed these past years.
2. Chitosan: Nature and Different Uses
Chitosan is a linear polysaccharide composed of randomly distributed β-(1→4)-linked
D-glucosamine and N-acetyl-d-glucosamine, as presented in Figure 1. It is obtained from the treatment
of the chitin shells of shrimp and other crustaceans with an alkaline substance, such as sodium hydroxide
leading to a deacetylation process. It can also be obtained from fungal source. The percentage of
deacetylation can be determined by NMR spectroscopy, and it ranges from 60% to 100% in commercial
chitosans. The molecular weight of commercially produced chitosan ranges from 3800 to 20,000 Daltons.
Chitosan’s amino group has a pKa value of ~6.5, leading to significant protonation at neutral pH,
increasing with decreased pH and the percentage of deacetylation. This property makes chitosan
both water-soluble and bioadhesive, easily binding to negatively charged surfaces such as mucosal
membranes [10]. It is a biocompatible and biodegradable polymer that significantly enhances the
transport of polar drugs across epithelial surfaces [11]. Chitosan has a large number of commercial
and possible uses. In agriculture, chitosan can act as a seed treatment and biopesticide, helping plants
to control fungal infections and it is also used in winemaking to prevent spoilage [12,13]. In the field of
medicine, chitosan is used in bandages to reduce bleeding [14].
Chitosan is also proposed as a potential anti-infective agent. Thus, low molecular weight
chitosan has been shown to exhibit antiviral, antibacterial, and antifungal activities [15–17].
Among medical applications, the search for anti-infective agents to treat diseases caused by drug
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resistant microorganisms has been gaining increased attention. The addition of hydrophobic chains
onto the chitosan molecule by the reaction of N-acylation with maleic anhydride, making it amphiphilic,
highly improved its antimicrobial activity by increasing electrostatic interaction with the cell walls
of Staphylococcus aureus and Escherichia coli [18]. However, no activity of this modified polymer was
detected against the protozoan Leishmania amazonensis. As no cytotoxicity was observed, this system
appeared to be promising for further studies against bacteria [18]. In contrast, C-6 oxidized chitosan
derivative obtained from chemical chitosan oxidation that had been degraded by enzymes systems
such as endocellulase, hyaluronidase, hyaluronate lyase, chitinase, and other proteins, exhibited
low antileishmanial activity against Leishmania infantum LIPA 137 with an IC50 value at 125 µg/mL,
whereas the antibacterial activity was not significant at all [19]. These data highlight some clues about
how chemical modifications of the chitosan skeleton enhance its antileishmanial activity. In addition,
the immunostimulatory activity of chitosan with its capacity to induce Th1 cell responses could
also be valorized in the field of antileishmanial chemotherapy [20]. According to the Food Drug
Association (FDA), chitosan is a non-toxic, biodegradable, and biocompatible substance [21–24].
This enables chitosan also to be used to as drug delivery vehicle, either parenterally or integrated in
drug formulations for topical use [25]. Within this latter context, the added value of chitosan would
also be the acceleration of wound healing [26]. Such complementary and convergent properties could
possibly help reduce the disfiguring leishmaniasis scars post-leishmaniasis. Topical therapy is an
ideal treatment for simple CL because of the ease of administration and lower cost. Thus, chitosan
or chitosan derivatives could be part of a suitable mono or bi/tri-therapy for localized cutaneous
leishmaniasis or in combination with systemic therapies for more severe forms of the disease.
3. Activity of Chitosan and Its Derivatives on Leishmania Parasites
3.1. In Vitro Antileishmanial Activity of Chitosan and Its Derivatives
Several studies have described the in vitro activities of chitosan against Leishmania sp.
Thus, low molecular weight chitosan, with 95% degree of deacetylation, was completely effective at
concentrations of 100 µg/mL on promastigotes of L. major after 180 min of application [27]. In vitro
activities of chitosan and some of its derivatives have also been studied in depth against L. major
and L. mexicana, showing that the pH of the culture medium is critical for the activity against both
promastigotes and intramacrophage amastigotes [28]. Thus, chitosan and its derivatives appeared
approximately 7 to 20 times more efficient at pH 6.5 than at pH 7.5, and high-molecular-weight
chitosan was the most active. This activity is positively correlated with the level of protonation of the
polymer, allowing a better interaction with the negatively charged parasite membranes. Although
the production of nitric oxide and reactive oxygen species was stimulated by high-molecular-weight
chitosan in both uninfected and Leishmania-infected macrophages in a time- and dose-dependent
manner at pH 6.5, the antileishmanial activity of chitosan was found not to be mediated by these
metabolites. Analysis of the mechanism of action, based upon confocal imaging showed that
rhodamine-labeled chitosan was taken up by pinocytosis and accumulated in the parasitophorous
vacuole of Leishmania-infected macrophages [28]. This is the first demonstration of the mechanism of
chitosan uptake by Leishmania-infected macrophages and of its location within the parasitophorous
vacuole. Therefore, intrinsic antileishmanial activity of chitosan and its previously described
immunodulatory effect are promising for further exploration of the capacity of this polymer to
cure infected animals alone or in combination with antileishmanial drugs.
3.2. In Vivo Antileishmanial Activity of Chitosan on Cutaneous Leishmaniasis BALB/c Mice Model
Due to its biocompatibility, biodegradability, non-toxicity, and antimicrobial activity, chitosan is
one of the most investigated biopolymers for wound healing [29–31]. A wide variety of biomedical
applications have been reported for chitosan, especially for the treatment of cutaneous leishmaniasis.
A study was performed in BALB/c mice to evaluate the efficacy of nanochitosan films in the treatment
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of cutaneous leishmaniasis caused by an Iranian strain of Leishmania major [32]. The application of
nanochitosan film increased the reepithelialization rate, wound contraction rate, and the scar tissue
formation, and in combination with Glucantime® significantly reduced both lesion size and parasite
load. Nanochitosan films, when administered alone or in combination with Glucantime® by the
intraperitoneal route, were shown to enhance glutathione peroxidase (GPX) activity and decrease lipid
peroxidation and oxidative stress [32]. In other studies, low molecular weight chitosan, with 95%
degree of deacetylation, significantly reduced the mean size of dermal lesions in BALB/c mice infected
with an Iranian strain of L. major after a topical treatment at 200 and 400 µg/mL for 28 days compared
to the control group [27].
3.3. Pilot Clinical Study of Chitosan Efficacy on Cutaneous Leishmaniasis Lesions in Patients
After confirming the effectiveness of nano-chitosan films in the treatment of cutaneous
leishmaniasis in susceptible laboratory animals, a pilot clinical study was performed in 10 patients,
in the absence of a control group [33]. The safety and efficacy of a chitosan-based biocompatible
dressing was determined in patients affected by cutaneous leishmaniasis who were either unresponsive
to or who presented medical contraindications to standard treatments. The film was maintained
over the wound site for one week and was renewed every week until the healing was completed.
All patients showed either significant (30%) or complete (70%) re-epithelialization of the skin lesion as
well as microscopic negative results for amastigote forms of Leishmania after eight weeks of therapy.
It is notable that all cases were completely cured at 16 weeks post treatment, in the absence of allergic
reaction or infection. The fact that no failure was monitored in any patients after six months follow-up,
makes this a promising approach to therapy [33]. However, further investigations need to be carried
out by including a randomized double-blinded clinical trial with more patients.
4. Chitosan-Based Drug Loaded Formulations for the Chemotherapy of Cutaneous Leishmaniasis
4.1. Amphotericin B-Chitosan Nanoformulations
Amphotericin B (AmB) is an active agent against leishmaniasis, but its use is hampered by its
high toxicity. Although amphotericin B-deoxycholate (AmB-DOC) showed its ability to partially cure
the infection after intravenous administration, it can lead to dose-limiting side-effects mainly due to
nephrotoxicity. The importance of AmB in the treatment of leishmaniasis, explains why AmB is the
most studied drug to develop various strategies for bioavailability improvement.
A nano-sized chitosan AmB formulation was prepared by a phase separation method with a
drug loading efficiency of 90% [34]. In vitro, a strong reduction of AmB cytotoxicity was observed
with an improvement of activity. The slow drug release allowed a 98% cellular uptake of AmB.
In vivo, a significant reduction of lesions along with complete wound healing was observed [34].
This formulation is worth further study.
The evaluation of an AmB nanoparticles-delivery system, containing chitosan and chondroitin
sulfate (NQC-AmpB) in a Leishmania amazonensis BALB/c mice model was combined with an in vivo
biodistribution study showed that NQC-AmpB significantly reduced the lesion size and parasite
burden with higher IFN-γ and IL-12 rates, and lower rates of IL-4 and IL-10, in comparison to the
control groups. No significant toxicity was observed in the animals treated with NQC-AmpB at
the doses used of 1 mg/kg of AmpB for 10 days [35]. These data should be confirmed by clinical
trials, and the industrial scale-up with such a complex system should be compatible with limited cost
of production.
Solid lipid nanoparticles (SLNs) have previously emerged as an interesting substitute to polymeric
nanoparticles. SLNs loaded with AmB showed the advantage of combination between AmB
chemotherapy with the immunomodulatory effect induced by chitosan [36]. Solvent emulsification and
evaporation method were used to obtain uncoated and chitosan-coated AmB-loaded SLNs (AmB-SLNs).
The internalization of chitosan-coated AmB-SLN by J774A.1 cells was more efficient than those with the
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uncoated formulation, without hemolytic effect. The in vitro antileishmanial activity of chitosan-coated
AmB-SLN was higher than those of AmBisome® and Fungizone® [36]. TNF-α and IL-12 productions
were stimulated by chitosan-coated AmB-SLNs. In addition, this formulation exhibited a better in vitro
and in vivo safety profile than the commercial formulations. Therefore, AmB-SLNs have the required
qualities to be evaluated in vivo on experimental leishmaniasis models.
A more complex system, consisting of self assembled sodium alginate cross-linked AmB loaded
glycol chitosan stearate nanoparticles (AmB-SA-GCS-NP) was prepared using strong electrostatic
interactions between oppositely charged polymer and copolymer using the ionotropic complexation
method [37]. The nanocrystals obtained exhibited a size of 196 nm. Tagged FAmB-SA-GCS-NP
had significantly higher (~1.7) uptake by J774A.1 cells in comparison to tagged FAmB. The in vitro
antileishmanial activity, with IC50 values around 0.1 µg AmB/mL, and the in vivo reduction of
parasite burden by 70% showed that AmB-SA-GCS-NP had significant improved activity over AmB
alone. The decrease of in vitro and in vivo toxicities was ascribed to the monomeric form of AmB
within SA-GCS-NP, compared to plain AmB [37]. AmB-SA-GCS-NP presents the advantage of a
well-structured molecular organization leading to significant advantages in terms of activity and
toxicity to be explored further.
A mannose-anchored thiolated chitosan (MTC) amphotericin B nanocarrier was also developed and
characterized to improve AmB biocompatibility and antileishmanial activities [38]. These nanoparticles
were rod shaped with a size of ∼480 nm and elicited a 71-fold enhancement of drug uptake compared
to native AmB in both uninfected and AmB sensitive L. donovani-infected macrophages. Morever,
MTC nanocarriers retained and slowly released AmB over a 10-day period, whereas, with the native
drug, no AmB was detected after two days of treatment. Macrophage survival was evaluated at 90%
with MTC at the highest concentration of AmB tested (75 µg/mL) while it was only at 34.5% with the
native drug under the same conditions. The MTC-AmB formulation exhibited a 10-fold increase of the
in vitro antileishmanial activity compared to the native drug, with IC50 at 0.02 µg/mL and 0.26 µg/mL
for MTC-AmB and AmB, respectively. Moreover, permeation of MTC-AmB across the Caco-2 cell
monolayer was increased by 3-fold in comparison to pure AmB [39]. Pharmacokinetic studies have
shown that MTC-AmB half-life and oral bioavailability were increased by 3.3- and 6.4-fold compared
to pure AmB [39]. Moreover, oral administration of 50 mg/kg of MTC-AmB showed less hepato- and
renotoxicity compared to AmB. Accordingly, in L. donovani-infected mice, a large reduction of parasite
burden (89%) was observed after oral administration of 1 mg/kg MTC-AmB for seven days, in contrast
to the native drug (17%). This MTC-AmB formulation is promising as an oral administration of AmB
for leishmaniasis treatment.
A chitosan-based formulation, using N-palmitoyl-N-methyl-N,N-dimethyl-N,N,N-trimethyl-6-o-glycol
chitosan (GCPQ), was also used to encapsulate AmpB for oral treatments [40]. This chitosan derivative is
a self assembling nanoparticle internalized by enterocytes enhancing the bioavailability of hydrophobic
drugs [41,42]. The encapsulation of AmpB in GCPQ resulted in nanoparticles of a size of 216 and
35 nm, the bimodal size being due to an equilibrium established between drug filled particles and
empty micelles. Besides an oral bioavailabity of AmB-GCPQ nanoparticle, evaluated at 24%, this oral
formulation was shown to exhibit a comparable efficacy to parenteral AmBisome® in the treatement
of visceral leishmaniasis in vivo in L. infantum infected Balb/c mice, and also in murine models of
candidiasis and aspergillosis. This formulation also paves the way for a new oral treatment of visceral
leishmaniasis by using bioavailable AmB-encapsulated nanoparticles.
Chitosan nanoparticles modified with a ligand 4-sulfated N-acetyl galactosamine (4-SO4GalNAc),
called SCNPs, were loaded with AmB producing an AmB-SCNPs formulation with a mean particle
size of 333 nm, for an AmB improved delivery to infected macrophages [43]. In vitro studies using
J774A.1 macrophages showed an enhanced uptake of AmB-SCNPs in comparison with AmB loaded
unmodified chitosan NPs (AmB-CNPs). After intravenous administration to L. donovani infected
hamsters at a dose equivalent of 1 mg/kg/day of AmB for two days, AmB-SCNPs allowed a higher
AmB concentration within liver and spleen as compared to AmB-CNPs and reduced the splenic
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parasite burden by 75%, whereas AmB-CNPs and AmB alone caused 63 and 47% parasite burden
reduction, respectively, in Leishmania-infected hamsters [43]. These results were ascribed to the capacity
of 4-SO4GalNAc to target resident macrophages.
As AmB has a poor water solubility, chitosan nanoparticles and Anionic Linear Globular
Dendrimers (D) were synthesized and loaded with AmB leading to AK (Amphotericin B-chitosan),
and AD (Amphotericin B-Dendrimer) for the treatment of Leishmania major CL [44]. The results showed
that AmB could be loaded into both these polymers with a loading efficiency of more than 80% and the
AmB solubility was enhanced by 80 times for AK and 478 times for AD. In vitro studies revealed a
minimum of 90% cell uptake from a slow controlled drug release. No toxicity was observed in vitro
and in vivo for both nanodrugs and AK at 10 mg/kg reduced parasite burden to a greater extent
(by 83%) than AD did at 50 mg/kg. Further studies are required.
4.2. Paromomycin-Chitosan Nanoformulations
Paromomycin (PM), an aminoglycoside with antiprotozoal properties, is used for the treatment of
both VL and CL. However, it has limited intrinsic antileishmanial efficacy, low oral absorption and short
half-life demanding innovative strategies to optimize use [45]. Although PM is presently recommended
as an ointment (Leishcutan®) for the treatment of LCL caused by Leishmania major, efforts could be
made to improve topical treatments considering the physicochemical properties of this aminoglycoside.
One challenge is to enhance the accumulation of enough drug quantity within the dermis where
the infected macrophages dwell. Chitosan (CS) was used for the preparation by ionic gelation of a
PM-loaded mannosylated CS (MCS) nanoparticles using dextran (PM-MCS-dex-NPs). The particle size
of PM-MCS-dex-NPs was estimated at 246 nm, a mannosylation rate of CS at 17%, and an encapsulation
efficiency at 83.5%. Acidic media allowed for a better drug release. The mannosylation enhanced
the PM uptake by THP-1 cells by about three and four times in comparison to non-mannosylated CS
nanoparticles (PM-CS-dex-NPs) and PM solution, respectively. The mannosylation process was also
responsible for a seven-times increase in the selectivity index in comparison with the non-mannosylated
formulation [45]. Such results highlight the interest of the mannosylation process as an efficient targeted
delivery system.
Mannosylated thiolated chitosan (MTC)-coated PM-loaded poly(d,L-lactide-co-glycolide) (PLGA)
nanoparticles (MTC-PLGA-PM) were evaluated for their antileishmanial activity in vitro and
in vivo [46]. These particles are spherical with a size of 391 nm. Ex vivo permeation studies showed a
12.7-fold higher permeation of MTC-PLGA-PM compared to free PM. Cellular uptake was markedly
increased with the formulation (between 41.98 µg PM/106 cells and 43.11 µg PM/106 cells) by either
uninfected or PM-sensitive and -resistant L. donovani strains infected J774A.1 macrophages, compared
to free PM (between 0.714 µg PM/106 cells and 1.13 µg PM/106 cells). The in vitro antileishmanial
activity on L. donovani intramacrophage amastigotes was increased by 36-fold with MTC-PLGA-PM
compared to free PM. Moreover, the in vivo evaluation of antileishmanial activity revealed a 3.6-fold
reduction of parasite burden in L. donovani infected BALB/c mice treated with 20 mg/kg/day for 10 days
by oral route with MTC-PLGA-PM, compared to free PM. These chitosan-based PM nanoparticles
constitute a promising strategy for the treatment of visceral leishmaniasis.
4.3. Meglumine Antimoniate-Chitosan Nanoformulations
Mannosylated thiolated chitosan (MTC) and mannosylated thiolated chitosan-polyethyleneimine
(MTCE) were also used to incorporate antimonial compounds and analyze their antileishmanial
activity [47]. While meglumine antimoniate-loaded nanoparticles inhibited the trypanothione reductase
with a Ki at 2 µM, their macrophage uptake was 33.7- and 18.9-fold higher with MTCE and MTC,
respectively, in comparison to Glucantime®. Moreover, the antileishmanial activity was improved by
14.4- and 7.4-fold with MTCE and MTC, respectively, compared to Glucantime® alone. This formulation
designed to improve the therapeutic efficacy of antimonials would have been worthy of in vivo
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antileishmanial evaluation; however, the probability of development and marketing of a new antimonial
formulation in the future is non-existent.
Microspheres containing different proportions of chitosan, maltodextrin (Glucidex® 19D and
6D), caprylic/capric triglyceride (Labrafac®), PEG-40 hydrogenated castor oil (Cremophor RH40®)
and lecithin (Lemucithin 100®) were also used to formulate meglumine antimoniate [48]. All the
formulations designed exhibited IC50 values between 3.80 to 9.53 µg SbV/mL against L. infantum
promastigotes, which is considerably lower than the IC50 of Glucantime® at 112.26 µg SbV/mL, this
last value is unusual as antimonials are known to have very poor activity against promastigotes.
An improvement of activity was also observed on intramacrophage amastigotes for two microspheres
among the other formulations, with IC50 at 31.94 SbVµg/mL and 6.64 µg SbVµg/mL, compared to
Glucantime® with IC50 values of 176 µg SbV/mL, without cytotoxic effects. Interestingly, substantial
activity was obtained with the excipient chitosan on both L. infantum promastigotes and amastigotes,
with IC50 at 112.64 µg chitosan/mL and 100.81 µg chitosan/mL, respectively. Therefore, by lowering the
toxic effects of meglumine antimoniate, these chitosan-based formulations would offer new possibilities
for the treatment of visceral leishmaniasis, however, the development of new antimonials is not
presently encouraged.
4.4. Rifampicin Loaded Nanotransfersomes (NTs) Incorporated in Chitosan Gel
Rifampicin was able to significantly reduce the lesion size in a L. amazonensis murine model after
an intraperitoneal treatment, but clinical trials in humans were not convincing [49]. Another study
reports on 39 patients with cutaneous leishmaniasis provoked by Leishmania major who were treated
with rifampicin alone or in combination with isoniazid. About 50% of the patients were cured two
months after starting the treatment and no significant difference was found between both the treatment
regimens [50]. A clinical study including patients affected by L. tropica and having received a drug
combination rifampicin-omeprazole appeared successful, but this study did not include patients
treated with rifampicin alone [51]. Considering these controversial data obtained by parenteral
route, a topical application was prepared consisting of rifampicin (RIF)-loaded nanotransferosomes
(NTs) incorporated in a chitosan gel [52]. The particle size was 190 nm, with an 83% encapsulation
efficiency. Some advantages have been observed by using this formulation such as a three times higher
permeation rate than the RIF solution, an enhanced macrophage uptake, and better in vitro and in vivo
antileishmanial activities making this formulation worthy of further studies [52].
4.5. Curcumin-Chitosan Nanoformulations
Curcumin (Cur) is a natural polyphenolic compound derived from the plant Curcuma longa
which has been well studied for its anti-cancer, anti-inflammatory, anti-bacterial, and anti-malarial
properties [53–56]. Several studies have reported the antileishmanial activity of Cur, which is
presumably mediated through programmed cell death [57,58]. Cur-loaded mannose-functionalized
chitosan nanoparticles (Cur-MCN) have been prepared by mannose-conjugated chitosan to better
target macrophages in visceral leishmaniasis [59]. This formulation was not cytotoxic for J774A.1 cell
line. When evaluated in vivo in a L. donovani-infected hamster model, it had the capacity to reduce the
spleen parasite burden to a greater extent than unconjugated chitosan nanoparticles [59].
4.6. β-. Lapachone-Chitosan
β-Lapachone (β-LP) is a o-naphthoquinone obtained from the bark of the Lapacho tree
(Bignoniaceae family, Tabebuia sp.) which exhibits a wide range of biological activities such as
antitumor, antifungal, antibacterial, and antitrypanosomal properties [60]. Besides promoting wound
healing, this natural compound has also reported antileishmanial activities on several Leishmania
species [61–63]. However, due to a poor solubility in aqueous solutions, β-LP has to be formulated for
the topical treatment of CL. A study focused on a topical treatment of a formulation of β-LP that cures
lesions of CL without leaving scars [64]. As lesions are produced by an uncontrolled and persistent
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inflammatory immune response, the strategy consisted in evaluating β-lapachone (β-LP) loaded in
lecithin-chitosan nanoparticles (NP) in order to concentrate the drug into the dermis, where parasites
dwell, and also promote an efficient wound healing response through a better permeation through
the skin. On the Leishmania major infected BALB/c mice model, a topical treatment with β-LP-NP
was not able to reduce the parasite burden, but the lesion progression was efficiently stopped [64].
The anti-inflammatory activity was assessed by immuno-histopathological assays in lesions and
quantitative mRNA assays in draining lymph nodes. The anti-inflammatory activity of β-LP-NP led to
a down-regulation in IL-1β and COX-2 expression and reduced neutrophils infiltration [64]. Such a
moderate activity needs further investigations on other leishmaniasis experimental models.
4.7. Betulinic Acid-Chitosan
Betulinic acid (BA) is a lupane-type triterpenoid pentacyclic compound that can be isolated
from many plant species or obtained from its metabolic precursor, botulin [65]. This natural product
presents several biological properties including anti-HIV, antitumor, and antiparasitic activities,
in particular against the kinetoplastids Trypanosoma cruzi and several species of Leishmania [66–68].
In L. donovani, BA has been shown to induce apoptosis through DNA topoisomerase I and I inhibition [68].
More recently, BA was loaded into nanochitosan (K) to try to improve its therapeutic effects and
decrease its adverse effects on a Leishmania major-infected BALB/c mice [69]. The synthesized K particles
exhibited a size of 102 nm, whereas BA-nanochitosan (BK) had a size of 124 nm and a drug loading
efficiency of 93%. The drug uptake of 97% to 98% by cells, and a slow B release without toxicity
were significant advantages. The activity of BK in the L. major BALB/c mice model at 20 mg/kg by
intraperitoneal route for six weeks (alternative days) was shown to enhance the wound healing [69].
Considering these results, BK should be further studied to confirm its interest in the treatment of CL.
4.8. Ursolic Acid-Chitosan
Ursolic acid (UA) is a pentacyclic triterpenoid identified in the epicuticular waxes of apples having
anti-inflammatory, anti-bacterial, anti-diabetic, and also antileishmanial activities. UA showed in vitro
and in vivo activities in VL and CL experimental models after parenteral and topical applications,
respectively [70]. These promising activities led to the development of drug delivery systems to
reduce side effects. Therefore, a UA loaded N-octyl-chitosan surface decorated nanostructured lipid
carrier system (UA-NLC) was prepared and characterised for the treatment of VL [71]. UA-NLC
exhibited a nano size range from 103.7 to 143 nm with 12% drug loading capacity and an entrapment
efficiency of 88%. When compared to the macrophage uptake of the UA free form, the formulation had
increased uptake of 3 to 12 times depending on the parasite strain. UA-NLC was active in vivo on the
L. donovani/hamster model by suppressing the parasite burden by 98%.
4.9. S-Nitroso-Mercaptosuccinic Acid–Loaded Chitosan Nanoparticles
Nitric oxide (NO)-donors are an attractive option for killing of intracellular parasites.
However, they are too chemicaly unstable to be used easily in antileishmanial therapy. Therefore, there is
a need for a drug targeting strategy to allow an adapted NO-donor delivery. For this
S-nitroso-mercaptosuccinic acid was encapsulated into chitosan nanoparticles (NONPs) for an
antileishmanial evaluation on Leishmania amazonensis [72]. This formulation was not cytotoxic and a
reduction of the number of intramacrophage amastigotes was observed. This formulation is worth
further investigations in order to cure cutaneous leishmaniasis.
4.10. Chitosan Polymer as a Booster for Drug Efficacy
Previous data from the Paris-Saclay group showed that chitosan particles with typical flat surfaces,
called platelets, were able to act as a booster of AmB deoxycholate activity against Candida albicans
and C. glabrata [73,74]. Platelets have been synthesized through a hierarchical self-assembly process
between chitosan hydrophobically-modified with oleic acid and α-cyclodextrin in water [75]. In vitro
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evaluations showed that platelets exhibited intrinsic antileishmanial activity on Leishmania major
amastigotes, whereas native chitosan (average molecular weight Mw = 250,000 g/mol, degree of
deacetylation: 85%) did not. Furthermore, an additive combination effect was observed between AmB
deoxycholate and chitosan platelets with a Fractional Inhibitory Concentration Index value (FICI) at
1.213. The immunohistochemical and histological analysis of skin lesions of mice infected with L. major
and treated with this AmB deoxycholate and chitosan platelets combination exhibited a reduction
of the inflammatory granuloma and parasite load in comparison with AmB deoxycholate alone [75].
This study underlines the potential interest of a combination of chitosan platelets and AmB as a strategy
to cure CL.
Another study focused on the capacity of drug unloaded poly (isobutylcyanoacrylate) nanoparticles
coated with chitosan (Cs-NPs) to be active after topical application [76]. No cytotoxicity was observed
with this formulation on fully differentiated Caco/TC7 and HT29/MTX cells at 25 µg/mL [77]. In vitro
and in vivo evaluation demonstrated an intrinsic antileishmanial activity of Cs-NPs. Daily topical
applications on three consecutive weeks on L. major infected mice showed that Cs-NPs combined with or
without AmB-DOC led to a significant reduction of the parasite load and a partial healing of the lesions
that was confirmed by histological studies, in comparison with nontreated mice. The morphology of
parasites was affected as shown by transmission electron microscopy: L. major promastigotes incubated
with Cs-NPs revealed parasitic vacuoles and alterated shape and swelling of mitochondria [76].
4.11. Drug Combined Formulations
4.11.1. Amphotericin B-Miltefosine-Chitosan Lipid Nanoparticles
In another biocompatible and biodegradable system, miltefosine (HePC or hexadecylphosphocholine)
and AmB have been combined within a chitosan anchored Nanostructured Lipid Carrier (CNLC)
leading to HePC-AmB-CNLCs and Tween-80-AmB-CNLCs to get more antileishmanial efficacy [78].
The entrapment efficiency of AmB was about 85% for HePC-AmB-CNLCs with a mean size of
particles of 150 nm. The HePC loading efficiency was not determined. The in vitro AmB release
from the formulation was slow, corresponding to 65% after a 24 h incubation period for both
HePC-AmB-CNLCs and Tween-80-AmB-CNLCs. There was an increased uptake of FITC-HePC-CNLCs
over FITC-HePC-NLCs in the J774A.1 cell line by FACS study. Both HePC-AmB-CNLCs and Tween
80-AmB-CNLCs were not haemolytic or cytotoxic. In addition, HePC-AmB-CNLCs were more active
than Tween 80-AmB-CNLCs in vitro and in vivo in L. donovani- infected hamsters. When administered
by the intravenous route, HePC-AmB-CNLCs resulted in an increase of AmB concentration in liver
and spleen [78]. Despite the possible interactions between AmB and miltefosine molecules through
their respective lipophilic groups and their common affinity to sterols, these results suggested an
interesting opportunity to deliver AmB through HePC stabilized chitosan anchored nanostructured
lipid carriers with decreased side effects. Moreover, such an approach has the potential to limit drug
resistance emergence.
4.11.2. Paromomycin-Selenium-Chitosan Hydrogel
An original selenium derivative, named bis-4-aminophenyldiselenide, exhibited an IC50 value
of 5.6 µM against L. major intracellular amastigotes, justifying further in vivo investigation [79].
Bis-4-aminophenyldiselenide was formulated with paromomycin in chitosan hydrogels and an
evaluation of ex vivo permeation and retention in skin layers was carried out by using pig ear skin
in Franz diffusion cells. In these conditions, less than 2% to 4% of the diselenide drug was able to
penetrate and permeate through the skin, whereas the percentage of paromomycin penetration was in
a range from 25% to 60% without important retention within the skin. This formulation was not able
to increase lesion regression and reduce parasite burden on a L. major infected BALB/c mice model as
the result of its inability to deliver the selenium derivative [79].
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4.11.3. Antimony-Titanium-Chitosan
Nanoassemblies of chitosan-titanium dioxide (TiO2) nanoparticles (NPs) loaded with Glucantime®
were designed for getting an advantage over their possible additive effects against L. major [80].
The nanoassemblies with the optimal ratio by using 12.5 mg Glucantime®, 25 mg chitosan, and 6 mg TiO2
NPs were prepared and characterized for their physico-chemical characteristics, and mainly loading and
release efficiency of drug from nanoassemblies. When evaluated in vitro against L. major promastigotes,
TiO2 NPs exhibited similar activity as those with Glucantime® alone. However, nanoassemblies were
able to decrease both promastigote and intramacrophage amastigote proliferation by 13 and four
times, respectively, compared to Glucantime® alone, after a three-day exposure at 50 µg/mL final
concentration [80].
5. Immunomodulatory Effect of Chitosan
Chitin, as chitosan, is considered to be able to stimulate the immune system. A comparative
study was therefore performed considering the protective effects of microparticles (MP) of both
these polymers on a L. major BALB/c mouse model [81]. The MP size was less than 40 µm. After a
subcutaneous infection of BALB/c mice with promastigotes, chitin or chitosan MPs were administered
by subcutaneous route over two weeks with two-day intervals. At the autopsy, the lesion sizes were
10 times and five times smaller after chitin and chitosan administration, respectively, in comparison
with the lesion size of control group. In the same manner, the parasite load of the lymph nodes was
more reduced by chitin MPs than by chitosan MPs [81]. In addition, chitin MPs enhanced IL-10 and
TNF-α productions whereas chitosan MPs did not. This study clearly demonstrates the advantage of
chitin over chitosan as an immunomodulator in the L. major murine model.
In order to get an immunoadjuvant effect to AmB therapy, AmB loaded pluronic F127 (PF 127)
micelles were coated with chitosan (Cs-PF-AmB-M), giving them macrophage targeting properties.
This formulation was about eight to 10-fold less cytotoxic than AmB suspension [82]. Flow cytometry
revealed that Cs-PF-FITC-M was more internalized by J774A.1 macrophages than PF-FITC-M. In vitro
and in vivo antileishmanial activities of Cs-PF-AmB-M were encouraging with a stimulation of a Th1
immune response. The intravenous administration of the formulation had no effect on blood urea
nitrogen and plasma creatinine levels and the pharmacokinetic data demonstrated that Cs-PF-AmB-M
was able to circumvent the classical AmB nephrotoxicity [82]. From these results, Cs-PF-AmB-M
appears to be a possible formulation candidate combining both immunological and therapeutic targets,
without acute toxicity for the treatment of visceral leishmaniasis.
Nanometric amphotericin B (AmB)-encapsulated chitosan nanocapsules (CNC-AmB) have been
prepared using a polymer deposition technique mediated by nanoemulsion template fabrication [83].
The presence of chitosan was beneficial to CNC-AmB stability in the presence of protein and Ca(2+).
In vitro, CNC-AmB was less toxic to both J774A.1 cells and erythrocytes than conventional AmB
formulations such as Fungizone® and AmBisome®. CNC-AmB was active both in vitro on L. donovani
intramacrophage amastigotes with an IC50 value at 0.2 µg/mL and in vivo on L. donovani-infected
hamsters with 86% splenic parasite burden reduction after an intraperitoneal treatment on five
consecutive days, making a total dose of 5 mg AmB/kg of hamster body weight. These activities were
positively correlated with the upregulation of tumor necrosis factor alpha (TNF-α), interleukin-12
(IL-12), and inducible nitric oxide synthase and with the downregulation of transforming growth
factor β (TGF-β), IL-10, and IL-4 [83]. CNC-AmB can therefore be considered as an immunoadjuvant
chemotherapy delivery system most likely cheaper than AmBisome®.
6. Chitosan and Chitin for Antileishmanial Vaccines
There are a number of Leishmania vaccines in development [84], all with limitations but some now
making progress in clinical trials [85]. Chitosan has potential roles in vaccine development both as
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a delivery vehicle for requisite antigens and as an adjuvant, on which there have been few studies,
for leishmaniasis [86].
6.1. Leishmania Antigens Encapsulated in Chitosan Nanoparticles
A first generation Leishmania vaccine consisting of a whole Leishmania lysate antigen (WLL) and
soluble Leishmania antigens (SLA) were encapsulated in chitosan nanoparticles and studied in BALB/c
in a murine model of leishmaniasis at the level of immune response [87]. An ionic gelation method was
used to load chitosan nanoparticles with antigens, according to a polymer/antigens optimised ratio.
The formulation was characterized and used for BALB/c mice immunization by subcutaneous route
versus antigens alone three times with two-week intervals. The results were disappointing, as a mixed
Th1/Th2 immune response was obtained, whereas a Th1-type immune response was expected [87].
6.2. Leishmania Superoxide Dismutase Loaded Chitosan Nanoparticles
A study reports on the loading of recombinant Leishmania superoxide dismutase (SODB1) onto
chitosan nanoparticles [88]. These particles were prepared by using ionotropic gelation and were
physicochemically characterised. Then, a study was performed on the L. major BALB/c mice model
through immunization by the subcutaneous route in three doses at three weekly intervals. The IgG2a
and IgG1 analysis in blood, performed three weeks after the last injection, indicated a significant
increase of the IgG2a/IgG1 ratio, whatever the administration scheme with one or three SODB1
nanoparticles doses. These encouraging results suggest that SODB1 loaded chitosan nanoparticles are
able to stimulate the cell-mediated Th1 immunity, suitable for the development of nanovaccines [88].
7. Conclusions
Leishmaniases mainly affect poor populations, therefore the therapy/vaccine strategies should
be both reliable and cheap, making them affordable for patients and populations. It is expected
that any particulate formulation, such as AmBisome®, significantly increases the treatment cost,
and if the formulations are more sophisticated, the probability of pharmaceutical development will
be jeopardized.
In this context, the first advantages of chitosan are its ease of production at low cost and its
biodegradability. This review has highlighted interesting data, paving the way to further investigations
on leishmaniasis both in therapeutic and vaccine research. However, despite the number of data
collected, it was not possible to highlight the most relevant physico-chemical characteristics of the
formulations responsible for the best in vitro selectivity index and in vivo activity, as many parameters,
i.e., the nature of the polymer, the particle size, the zeta potential, the loaded drugs, and the different
strains and protocols used for their biological evaluation are intimately entangled. Further studies
focused only on AmB, for example, would be useful for a strict comparison between the most
promising formulations by using the same in vitro and in vivo models of experimental leishmaniasis.
The second advantage of chitosan is its intrinsic antileishmanial activity. Thus, when combined
with another drug, it acts as a booster and, to some extent, it can also be considered as an active
principle for drug combination. Few studies have focused on the mechanism of action of chitosan
on Leishmania. It is known that Leishmania sp. expresses chitinase activity thought to be important
in parasite-sandfly interactions and transmission of the parasite to the vertebrate host [89]. Even if
chitinases have the unique ability to hydrolyse GlcNAc-GlcNAc bonds, making these enzymes capable
of hydrolysing chitin, they are able to hydrolyse, to some extent, partially acetylated chitosan as
well [90]. Thus, the importance of leishmanial chitinases in the mechanism of action of chitosan is
worthy of further consideration if GlcNAc oligomers exhibit intrinsic antileishmanial activity.
Significative efforts on chitosan research have been carried out for a decade in antileishmanial
chemotherapy by association with drugs, and mainly AmB, as this drug is a star in antileishmanial
therapy. However, improvements in activity are required via different strategies including various
chitosan formulations. Thus, several parameters such as the degree of deacetylation, the particle size,
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and the administration route gave various possibilities and promising perspectives of chitosan for
therapies and vaccines.
Supplementary Materials: The following are available online, Table S1: Physico-chemical characteristics of
the chitosan-based antileishmanial formulations. ND: Not determined, Table S2: Biological activity of the
chitosan-based antileishmanial formulations. ND: Not determined; AP: Active principle
Funding: This research received no external funding.
Conflicts of Interest: The authors declare no conflict of interest.
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